Hisamitsu Pharmaceutical CoFSE:4530 89 Pretax Margin % is 16.01% as of Nov. 2025, which is 1% below its 10-year median of 16.21. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 955 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 68.9% on this metric.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
FSE:4530'
s Pretax Margin % Range Over the Past 10 Years
Min: 10.65 Med: 16.21 Max: 20.55
Current: 14.51
FSE:4530's Pretax Margin % is ranked better than 68.9% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs FSE:4530: 14.51
Hisamitsu Pharmaceutical Co (FSE:4530) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Hisamitsu Pharmaceutical Co Pretax Margin % Related Terms
Hisamitsu Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Pretax Margin % of 16.01% as of Nov. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 16.21. Over the past decade, Hisamitsu Pharmaceutical Co's Pretax Margin % has ranged from 10.65 to 20.55. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 955 companies in the Drug Manufacturers industry, placing it in the top 31.1%.
Is Hisamitsu Pharmaceutical Co's Pretax Margin % too high?
Hisamitsu Pharmaceutical Co's current Pretax Margin % of 16.01% is near median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 10.65 to a high of 20.55. The Drug Manufacturers industry median Pretax Margin % is 7.28. Hisamitsu Pharmaceutical Co's value of 16.01% is 119.9% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #297 out of 955 companies for Pretax Margin %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median Pretax Margin % is 7.28. Hisamitsu Pharmaceutical Co's value of 16.01% is 119.9% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Pretax Margin % has ranged from 10.65 to 20.55 over the past decade. While the company's 10-year median is 16.21 vs. the industry median of 7.28, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Pretax Margin % of 16.01% is 119.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Pretax Margin % is 16.01%, which is near median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Pretax Margin % of 16.01%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Pretax Margin % is 16.01%, which is near median its 10-year median of 16.21 and 119.9% above the Drug Manufacturers industry median of 7.28. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Pretax Margin % is 16.01% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Pretax Margin %: 16.01% (near median its 10-year median of 16.21)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 119.9% above the Drug Manufacturers median (#297 of 955)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
